First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV TestingSINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home. BD annou ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or West Pharmaceutical Services (WST) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our ...

FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy, with this installment hig ...

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its series of product launches over the past few months. The optimism led by a solid first-quarter fiscal 2024 performance and a few regulatory approvals are expected to contribute further. However, macroeconomic concerns and forex volatility persist.Over the past year, this Zacks Rank #3 (Hold) stock has lost 7.2% against the 7.3% rise of the industry and 19.2% growth of the S&P 500.Th ...

| --- | --- | --- | --- | --- | |--------------------------|-------|-----------------------|-----------|-------------------| | | | | | | | | | | | | | | | | | | | Q1 FY24 February 1, 2024 | | Earnings Presentation | | | | | | | Advancing | the | | | | | | world of healthTM | Caution Concerning Forward-Looking Statements This presentation and accompanying audio webcast contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and ...

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Conference Call February 1, 2024 8:00 AM ET Company Participants Greg Rodetis - SVP, Treasurer & Head of IR Tom Polen - Chairman, President & CEO Christopher DelOrefice - EVP & CFO Michael Garrison - EVP & President, Medical Segment Dave Hickey - EVP & President, Life Sciences segment Conference Call Participants Rick Wise - Stifel Travis Steed - Bank of America Vijay Kumar - Evercore ISI Lawrence Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Patr ...

Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $2.68 in the first quarter of fiscal 2024, down 10.1% year over year. The figure topped the Zacks Consensus Estimate by 12.1%.The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.GAAP EPS for the quarter was 96 cents, reflecting a decline of 43.5% from the year-earlier figure.Revenues in DetailBD registered revenues of $4.71 billion in the fis ...

For the quarter ended December 2023, Becton Dickinson (BDX) reported revenue of $4.71 billion, up 2.6% over the same period last year. EPS came in at $2.68, compared to $2.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.74 billion, representing a surprise of -0.64%. The company delivered an EPS surprise of +12.13%, with the consensus EPS estimate being $2.39.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Becton Dickinson (BDX) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.13%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $3.42 per share when it actually produced earnings of $3.42, delivering no surprise.Over the last four quarters, t ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence (AI)-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and pre-cancer using whole-slide imaging.The Techcyte platform is compatible with liquid-based cytology preparations, including BD SurePath Liquid-based Pap Test vial. It also aims to be compatible w ...